Skip to content

Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV

Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV and Elevated Triglycerides

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06058845
Enrollment
50
Registered
2023-09-28
Start date
2023-10-01
Completion date
2024-01-30
Last updated
2024-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic Syndrome, Dyslipidemias, Hypertension

Keywords

Vascular function, Tamarindus indica, Lipid metabolism, Glucose metabolism, Polyphenols, HIV

Brief summary

The increasing burden of metabolic disturbances among People Living with HIV especially in developing countries has posed need for scientifically-proven, innovative, sustainable and cost-effective local adjuvant remedies to supplement conventional medical interventions. The goal of this clinical trial is to test the potential of Tamarindus indica fruit juice to improve cardiometabolic health of PLWH and elevated Triglycerides (TG). The main aims it aims to answer are to; * evaluate the efficacy of T. indica fruit juice on selected markers of lipid and glucose metabolism, and vascular health. * investigate a possible dose-response relationship on cardiometabolic control following intake of varying concentrations (fruit pulp percentages) of T. indica fruit juice. Participants will be required to consume 600 ml of either 10% or 30% fruit pulp juice a day for 30 days. From the baseline measurements, participants will be asked to comeback for repeat measurements after 14 days and finally on the 3oth day (Endline). Researchers will compare the groups that will be expose to the two juice prototypes to determine potential differences in TG levels.

Detailed description

Suboptimal cardiometabolic health is on a disproportional rise in Low- and Middle-Income Countries (LMICs). In sub-Saharan Africa (SSA), cardiometabolic dysfunction is being exacerbated by the ongoing nutrition transition, that has seen a change from traditional diets to fast and ultra processed foods rich in sugar, fats, and salt coupled by low physical activity (Kiyimba et al., 2022). Similarly, chronic inflammatory diseases such as HIV can aggravate cardiometabolic risks (Todowedo et al., 2019). Beyond conventional nutrients, fruits and vegetables have ubiquitous amounts of bioactive components including polyphenols, alkaloids, saponins, and terpenes and terpenoids, with polyphenols being the most ubiquitous of all. Dietary polyphenols are a diverse category of secondary plant metabolites that represent the largest group of naturally occurring antioxidants with cardioprotective benefits (Rijha et al., 2022 and Quero et al., 2020). Our recent inventory study of Uganda's IFV with purported cardiometabolic benefits, highlighted the popularity of Tamarindus indica as a local adjuvant therapy for cardiometabolic risks among Ugandan communities (Kiyimba et al., 2023). T. indica, is a leguminous tree belonging to the family Fabaceae with a wide range of bioactive constituents in varying levels- the highest being polyphenols followed by alkaloids, saponins, and terpenoids in that order (Luca et al., 2019 and Penev et al., 2016). Therefore, the aim of this trial is to evaluate the efficacy of T. indica fruit juice (added to patients' usual diets) on selected cardiometabolic risk markers of PLWH under the community-based HIV care model in Uganda in a proof-of-concept clinical trial. Two blinded juice prototypes of 10% and 30% fruit pulp packaged in amber bottles each consisting of 300mls will be supplied by the Uganda Natural Chemotherapeutics Research Institute. This is a single centre, 2-arm, 4 weeks randomised, double-blinded parallel trial with equal allocation ratios. The study participants will be randomly allocated to consume twice-daily 600 mL of either 10% or 30% pulp of T. indica fruit juice. Both participants and the study team will be blinded to the intervention materials. Measurements will be performed at three different timelines: Baseline, Week two of the study, and Endline (week four of the study). Compliance to the study protocol will be confirmed by weekly telephone inquiries, and by counting the returned empty juice bottles or unused study products at each follow-up visit. Participants will be asked to maintain their habitual dietary regimen. The two juice prototypes will be blinded by assigning a secret code to each of the intervention products. As such, blinding of the investigators and participants will be undertaken to ensure a double-blind intervention. Moreover, the statistical analyses of the main endpoints will be done before breaking the intervention product concealment.

Interventions

DIETARY_SUPPLEMENTTamarindus indica fruit juice_A

The participants will be exposed to 10% Tamarind pulp juice

DIETARY_SUPPLEMENTTamarindus indica fruit juice_B

The participants will be exposed to 30% Tamarind pulp juice

Sponsors

Mildmay Uganda Limited
CollaboratorOTHER
KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Both participants and the study team will be blinded to the intervention materials. The two juice prototypes will be blinded by assigning a secret code to each of the intervention products. As such, blinding of the investigators and participants will be undertaken to ensure a double-blind intervention. Moreover, the statistical analyses of the main endpoints will be done before breaking the intervention product concealment.

Intervention model description

This is a single centre, 2-arm, 4 weeks randomised, double-blinded parallel trial with equal allocation ratios (1:1)

Eligibility

Sex/Gender
ALL
Age
30 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Triglycerides ≥150 mg/dL * TLD regimen (ART) for ≥12 months * 95% ART adherence in last 6 months * Virally suppressed (most recent results viral load suppressed within the last 12 months) * PLWH aged ≥30≤60 years. * No plans to change location in the next 6 months

Exclusion criteria

* Taking dietary supplements * TB co-infection, renal failure disease, liver cirrhosis, chronic pancreatitis * Pregnancy and Lactation or regular sport activity * Parallel participation in another clinical trial * On treatment for; dyslipidemia, hypertension or diabetes and oral hypoglycemic drugs * Very low blood pressure (\< 90/50 mmHg) * Not willing to consent or unable to consent

Design outcomes

Primary

MeasureTime frameDescription
Changes in the concentrations of Triglycerides30 daysA 10 mg/dL reduction in plasma triglycerides

Secondary

MeasureTime frameDescription
Changes in the concentrations of LDL-c30 daysReduction in plasma LDL-c
Changes in the concentration of HDL-c30 daysincrease in plasma HDL-c
Changes in the concentrations of Fasting Blood Glucose (FBG)30 daysReduction in FBG
Changes in Pulse wave velocity (m/s)30 daysMeasure of arterial stiffness (improvement in vascular function)
Changes in mmHg of Blood pressure30 daysImprovement in both systolic and diastolic blood pressure
Changes in the concentrations of Total cholesterol30 daysReduction in plasma cholesterol

Other

MeasureTime frameDescription
Changes in Body weight30 daysreduction in body weight
Changes in BMI30 daysreduction in BMI
Changes in Kg of body's fat mass30 daysImprovement in fat mass (reduction)
Changes in Waist circumference (WC)30 daysReduction in WC

Countries

Uganda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026